Table 2.

Effect of G-CSF on GVHD, relapse, non-relapse mortality, disease-free and overall survival

Outcome	Number Events/Evaluable	Hazard Ratio (95% confidence interval)	p-value
Grade 2-4 acute GVHD*
HCT without G-CSF	166/403	1·00
HCT with G-CSF	185/449	1·03 (0·83 – 1·27)	0·80
Grade 3-4 acute GVHD**
HCT without G-CSF	56/406	1·00
HCT with G-CSF	67/440	1·14(0·80 – 1·62)	0·48
Chronic GVHD***
HCT without G-CSF	153/409	1·00
HCT with G-CSF	142/445	0·99 (0·79 – 1·25)	0·97
Relapse♯
HCT without G-CSF	123/409	1·00
HCT with G-CSF	139/448	1·19 (0·93 – 1·52)	0·17
Non-relapse mortality╪
HCT without G-CSF	47/409	1·00
HCT with G-CSF	96/448	2·03 (1·43 – 2·88)	<0·0001
Disease-free survival∥
HCT without G-CSF	170/409	1·00
HCT with G-CSF	235/448	1·42(1·16 – 1·73)	0·0006
Overall survival$
HCT without G-CSF	111/409	1·00
HCT with G-CSF	173/448	1·52(1·20 – 1·94)	0·0005

Abbreviation:

HCT = hematopoietic cell transplant

G-CSF = granulocyte colony stimulating factor

GVHD = graft-versus-host disease

^*Model adjusted for disease: grade 2-4 acute GVHD was higher with myelodysplastic syndrome (HR 1·44, 95% CI 1·16 – 1·78, p=0·0009)

^**Model adjusted for disease and KPS: grade 3-4 acute GVHD was higher with myelodysplastic syndrome (HR 1·56, 95% CI 1·09 – 2·26, p=0·0157) and poor performance status (HR 1·65, 95% CI 1·16 – 2·33, p=0·0049)

^***Model adjusted for disease: chronic GVHD was higher with myelodysplastic syndrome (HR 1·31, 95% CI 1·03 – 1·65, p=0·0252)

^♯Model adjusted for disease risk index, KPS and condition regimen intensity: relapse was higher with intermediate (HR 3·11, 95% CI 0·99 – 9·80, p=0·0528) and high (HR 6·02, 95% CI 1·92 – 18·89, p=0·0021) DRI, poor performance status (HR 1·31, 95% CI 1·02 – 1·67, p=0·0335) and reduced intensity conditioning regimen (HR 1·51, 95% CI 1·16 – 1·96, p=0·0023)

^╪Model adjusted for disease and hematopoietic comorbidity score: non-relapse mortality was higher with myelodysplastic syndrome (HR 1·61, 95% CI 1·15 – 2·26, p=0·0051) and high comorbidity score (HR 1·55, 95% CI 1·11 – 2·16, p=0·0108)

^∥Model adjusted for disease risk index, KPS and condition regimen intensity: disease-free survival was lower with intermediate (HR 1·09, 95% CI 0·63 – 1·88, p=0·76) and high (HR 1·93, 95% CI 1·12 – 3·32, p=0·076) DRI, poor performance status (HR 1·39, 95% CI 1·14 – 1·69, p=0·0011) and reduced intensity conditioning regimen (HR 1·27, 95% CI 1·03 – 1·56, p=0·0233)

^$Model adjusted for KPS and hematopoietic comorbidity score: survival was lower with poor performance status (HR 1·51, 95% CI 1·19 – 1·90, p=0·0005) and high co-morbidity score (HR 1·30, 95% CI 1·03 – 1·65, p=0·0279).